Abstract 136P
Background
TNBC is more likely to metastasize within 3-5 years than other forms of breast cancer and has a median survival of 17.6-21.3 months after metastasis. Recent advances are promising, but trial results of immunotherapy-chemo combinations have resulted in a 3-year overall survival rate under 36% in a PD-L1 based cohort. There is thus an unmet need for innovations that lead to new treatments and improve outcomes for patients with TNBC in a personalized manner.
Methods
We have developed a platform to identify predictors of drug efficacy in TNBC. We assembled a panel of TNBC models that were screened with a library of 387 compounds. We integrated these results with multiomic molecular characterization to identify significant correlates of response to therapy. We used a panel of RNA correlates to characterize treatment naive PDXs to predict response to one of the most promising drugs, SN-38, a known active drug in TNBC. We evaluated SN-38 in vivo to ensure our in vitro screening was indicative of response.
Results
Following screening, we prioritized 35 drugs based on their activity and variance of response, identifying statistically significant molecular correlates of drug response for 27 out of 35 (77%) compounds. Focusing on SN-38, we identified a panel of multiomic correlates of response. Utilizing rapid RNA profiling, we predicted the response of previously untested PDXs to SN-38. Ex vivo evaluation of 5 PDXs revealed that our predictions were correlated with actual response. We identified that the autophagy and AKT pathways were elevated in models with poor response to SN-38; specific co-targeting these pathways with SN-38 was an effective strategy to identify rational, synergistic combinations. In vivo evaluation of irinotecan (SN-38 pro-drug) demonstrated correlation between our assayed response in vitro and response in mice.
Conclusions
We developed a platform that identified multiomic correlates of drug response for 27 compounds in TNBC. These correlates demonstrate promise in the prediction of response in molecularly unknown samples as well as the identification of companion therapeutics to synergize with a given therapy and help prevent or delay resistance. Going forward, we are working on the in vivo validation of these predictions of response and companion therapy combinations.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Breast Cancer Research Foundation, Susan G. Komen.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract